Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

Skin cancer, which includes the most frequent malignant non-melanoma carcinomas (basal
cell carcinoma, BCC, and squamous cell carcinoma, SCC), along with the difficult to treat …

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) are the mainstay of treatment of hormone
receptor+/human epidermal growth factor receptor 2-patients with advanced breast cancer …

Glioblastoma multiforme (GBM) is the most prevalent, treatment-resistant, and fatal form of
brain malignancy. It is characterized by genetic heterogeneity, and an infiltrative nature, and …

Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

The incidence of laryngeal carcinoma accounts for 1 to 5% of systemic malignancies and
ranks second among head and neck malignancies. Screening more effective targets are …

As cutting‐edge technologies applied for the study of body fluid molecular biomarkers are
continuously evolving, clinical applications of these biomarkers improve. Diverse forms of …

Esophageal adenocarcinoma (EAC) occurs following a series of histological changes
through epithelial-mesenchymal transition (EMT). A variable expression of normal and …

Background: Recent literature documented the expression of miRs in gastric cancer (GC),
however their clinical utility is still unclear. Methods and Results: 117 resected GCs were …